**References (Smith)**

**Homocysteine - from disease biomarker to disease prevention**.

Smith, A. D.; Refsum, H. *J Intern Med* 2021: 290¨826-854.

<http://dx.doi.org/10.1111/joim.13279>

**Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment. A randomized controlled trial**.

Smith, A. D.; et al. *PloS ONE* 2010: 5: e12244.

<http://dx.doi.org/10.1371/journal.pone.0012244>.

**Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial**.

de Jager, C. A.; et al. *Int J Geriatr Psychiatry* 2012: 27: 592-600.

<http://dx.doi.org/10.1002/gps.2758>

**Preventing Alzheimer's Disease-related gray matter atrophy by B-vitamin treatment**.

Douaud, G.; et al. *Proc Nat Acad Sci USA* 2013: 110: 9523-9528.

<http://dx.doi.org/10.1073/pnas.1301816110>

**Brain atrophy in cognitively impaired elderly: The importance of long-chain omega-3 fatty acids and b vitamin status in a randomized controlled trial**.

Jernerén, F.; et al. *Am J Clin Nutr* 2015: 102: 215-221.

<http://dx.doi.org/10.3945/ajcn.114.103283>

**Omega-3 fatty acid status enhances the prevention of cognitive decline by b vitamins in mild cognitive impairment** Oulhaj, A.; et al. *J Alzheimer's Dis* 2016: 50: 547-557.

<http://dx.doi.org/10.3233/JAD-150777>

**A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's Disease**.

Selley, M. L. *Neurobiol Aging* 2007: 28: 1834-1839.

**Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline**.

Yurko-Mauro, K.; et al. *Alzheimers Dement* 2010: 6: 456-464.

<http://dx.doi.org/S1552-5260(10)00040-3>

**Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline**.

Yurko-Mauro, K.; et al. *Alzheimers Dement* 2010: 6: 456-464.

<http://dx.doi.org/10.1016/j.jalz.2010.01.013>

**Homocysteine status modifies the treatment effect of omega-3 fatty acids on cognition in a randomized clinical trial in mild to moderate Alzheimer's Disease: The OmegAD study**.

Jerneren, F.; et al. *J Alzheimers Dis* 2019: 69 189-197.

<http://dx.doi.org/10.3233/JAD-181148>

**DHA status influences effects of B-vitamin supplementation on cognitive ageing: A post-hoc analysis of the B-proof trial**.

van Soest, A. P. M.; et al. *Eur J Nutr* 2022: 61: 3731-3739.

<http://dx.doi.org/10.1007/s00394-022-02924-w>

**Omega-3 fatty acids and their interactions**.

Smith, A. D.; et al. *Am J Clin Nutr* 2021: 113¨775-778.

<http://dx.doi.org/10.1093/ajcn/nqab013>